Evaluation of changes in ferritin levels during sucroferric oxyhydroxide treatment

Abstract

Background. A sub-analysis of a Phase III study was conducted to identify factors that might predict increased ferritin levels during long-termsucroferric oxyhydroxide (SO) treatment in hemodialysis patients. Methods. The open-label, multicenter, Phase III study assessed the efficacy and safety of SO 750-3000 mg/day for 52 weeks in Japanese patients with chronic renal failure and hyperphosphatemia. A total of 125 of 161 patients from the Phase III trial, and who had data for ferritin levels after 28 weeks of SO treatment, were evaluated. Results. Baseline ferritin was the strongest contributor (P